The conference agenda will focus on new translational advances in the treatment of cancer as well as provide updates on conventional therapies for a number of the most common tumour types. The meeting objectives are designed to introduce the audience to the latest information of targeted therapies and emerging therapies in the pharmaceutical development pipeline. The major emphasis will be on clinical aspects of cancer treatment with discussion of significant advances underlying the novel approaches still in preclinical development. The conference program is designed to meet the educational needs of scientists, physicians, medical oncologists, haematologists, researchers and other health care personnel practicing oncology in all disciplines as well as fellows in training who are interested in the development of new anticancer agents.